Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Sirion Therapeutics, Inc.245 enrolled

Overview

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

245

Conditions

Geographic Atrophy Dry Age Related Macular Degeneration

Interventions

FenretinideDRUG

Once daily 30 minutes after the evening meal for 24 months

Eligibility

Sex: ALLMin age: 50 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * males or females, 50 to 89 years of age * must have GA from AMD in one or both eyes Exclusion Criteria: * GA due to any disease other than AMD (eg, drug-induced)

Outcomes

Primary Outcomes

GA lesion progression

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.